Answers are grounded in this paper and cite their sources.
Esketamine shows promise for treating depression in patients with treatment-resistant cases, suggesting a new approach.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Conejero et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: